{"commentary":{"count":15,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":8,"podcast":5,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02651987\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CLARINET FORTE","nct_id":"NCT02651987","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=clarinet-forte-nct02651987. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"CLARINET FORTE","arms":[{"description":"One subcutaneous (SC) injection of lanreotide Autogel® 120mg every 14 days until disease progression or death or unacceptable toxicity or tolerability.","label":"Lanreotide Autogel®","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2019-10-24","type":"ACTUAL"},"conditions":["Pancreatic Tumours","Midgut Neuroendocrine Tumours"],"enrollment":{"count":99,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Lanreotide autogel 120 mg","type":"DRUG"}],"last_update":"2022-10-03","lead_sponsor":"Ipsen","official_title":"Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2019-10-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Median Progression Free Survival (PFS)","timeFrame":"From Day 1 up to Week 60 for the panNET cohort and Week 103 for the midgut NET cohort"}],"references":[],"start_date":{"date":"2015-12-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg","url":"https://clinicaltrials.gov/study/NCT02651987"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/clarinet-forte-nct02651987"}